Compare, Analyse Wockhardt with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 WOCKHARDT   MYLAN
EQUITY SHARE DATA
    WOCKHARDT
Mar-21
MYLAN
Dec-18
WOCKHARDT/
MYLAN
5-Yr Chart
Click to enlarge
High Rs5703,557-   
Low Rs1741,958-   
Sales per share (Unadj.) Rs249.31,636.8-  
Earnings per share (Unadj.) Rs62.244.4-  
Cash flow per share (Unadj.) Rs84.4350.9-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs302.31,770.7-  
Shares outstanding (eoy) m110.78514.50-   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.51.7 88.5%   
Avg P/E ratio x6.062.0 9.6%  
P/CF ratio (eoy) x4.47.9 56.1%  
Price / Book Value ratio x1.21.6 79.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m41,1881,418,753 2.9%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m7,6300-   
Avg. sales/employee Rs ThNM24,060.9-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM653.4-  
INCOME DATA
Net Sales Rs m27,620842,132 3.3%  
Other income Rs m1,5340-   
Total revenues Rs m29,155842,132 3.5%   
Gross profit Rs m12,575217,913 5.8%  
Depreciation Rs m2,460157,680 1.6%   
Interest Rs m2,49140,504 6.1%   
Profit before tax Rs m9,15919,729 46.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,273-3,139 -72.4%   
Profit after tax Rs m6,88622,867 30.1%  
Gross profit margin %45.525.9 175.9%  
Effective tax rate %24.8-15.9 -156.0%   
Net profit margin %24.92.7 918.1%  
BALANCE SHEET DATA
Current assets Rs m24,244470,246 5.2%   
Current liabilities Rs m31,182342,861 9.1%   
Net working cap to sales %-25.115.1 -166.1%  
Current ratio x0.81.4 56.7%  
Inventory Days Days3084 36.2%  
Debtors Days Days1293 13.0%  
Net fixed assets Rs m49,508163,360 30.3%   
Share capital Rs m554448 123.5%   
"Free" reserves Rs m32,9390-   
Net worth Rs m33,492911,033 3.7%   
Long term debt Rs m5,029983,297 0.5%   
Total assets Rs m73,7522,443,746 3.0%  
Interest coverage x4.71.5 314.5%   
Debt to equity ratio x0.21.1 13.9%  
Sales to assets ratio x0.40.3 108.7%   
Return on assets %12.72.6 490.3%  
Return on equity %20.62.5 819.1%  
Return on capital %30.23.2 951.1%  
Exports to sales %00-   
Imports to sales %1.80-   
Net fx Rs m5110-   
CASH FLOW
From Operations Rs m-2,873174,995 -1.6%  
From Investments Rs m14,701-90,453 -16.3%  
From Financial Activity Rs m-11,708-81,523 14.4%  
Net Cashflow Rs m1291,450 8.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.73 Rs / USD

Compare WOCKHARDT With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare WOCKHARDT With: GRANULES INDIA  CHANDRA BHAGAT PHARMA  AAYUSH FOOD & HERBS   EMMESSAR CHM  ABBOTT INDIA  



Today's Market

Sensex, Nifty Recover from Day's Low to End Higher; Maruti Suzuki Hits New High Post Q3 Results(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views On News

WOCKHARDT 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of WOCKHARDT for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of WOCKHARDT. Also includes updates on the valuation of WOCKHARDT.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better? (Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks (Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist (Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More
-->

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2022
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: How to Profit from Sensex 100,000
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

WOCKHARDT SHARE PRICE


Jan 25, 2022 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT

WOCKHARDT 8-QTR ANALYSIS

COMPARE WOCKHARDT WITH

MARKET STATS